FDA approves Eli Lilly’s weight loss drug Zepbound for sleep apnea, expanding use in U.S.

FDA approves Eli Lilly’s weight loss drug Zepbound for sleep apnea, expanding use in U.S.

An Eli Lilly & Co. Zepbound injection pen arranged in the Brooklyn borough of New York, US, on Thursday, March 28, 2024.  Shelby Knowles | Bloomberg | Getty Images The Food and Drug Administration approved Eli Lilly‘s blockbuster weight loss drug Zepbound for treating patients with the most common sleep-related breathing disorder, the drugmaker announced…

Read More